LCTL Is a Prognostic Biomarker and Correlates With Stromal and Immune Infiltration in Gliomas
Authors:
Open Access
- 15 October 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 1083
Abstract
Immune evasion in glioma strongly correlates with clinical outcomes; however, the molecular mechanisms driving the maintenance of immunosuppression remain largely unknown. Recently studies demonstrate that Klothos are aberrantly expressed in several cancers and are potential therapeutic targets in cancers. However, their roles are still unclear in glioma. Here, we show that LCTL is highly expressed in gliomas and that its expression is regulated by DNA methylation status at the promoter. LCTL expression is also found to be significantly associated with high tumor aggressiveness and poor outcomes for glioma patients. Mechanistically, results suggested that LCTL might play an important immunosuppressive role by recruiting immunosuppressive cells and regulating tumor-associated macrophages polarization, T cell exhaustion, and epithelial–mesenchymal transition through FGF signaling in glioma. Our results establish LCTL as a key biomarker for prognosis that could be considered a potential epigenetic and immunotherapeutic target for treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81802974)
This publication has 53 references indexed in Scilit:
- Cancer Stem Cells and Immunosuppressive Microenvironment in GliomaFrontiers in Immunology, 2018
- Primary brain tumours in adultsThe Lancet, 2018
- Gliosarcoma: a clinical and radiological analysis of 48 casesEuropean Radiology, 2018
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014Neuro-Oncology, 2017
- Immune Checkpoint in Glioblastoma: Promising and ChallengingFrontiers in Pharmacology, 2017
- γKlotho is a novel marker and cell survival factor in a subset of triple negative breast cancersOncotarget, 2015
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Malignant Gliomas in AdultsNew England Journal of Medicine, 2008
- Identification of a novel mouse membrane-bound family 1 glycosidase-like protein, which carries an atypical active site structureBiochimica et Biophysica Acta (BBA) - Gene Structure and Expression, 2002
- Mutation of the mouse klotho gene leads to a syndrome resembling ageingNature, 1997